P024: Updated efficacy and safety of SHR-A1811, an anti-HER2 antibodydrug conjugate, in heavily pretreated advanced solid tumors with HER2-expression or mutations: a global, multicenter, phase 1 study

IF 5.7 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Breast Pub Date : 2025-02-01 DOI:10.1016/j.breast.2025.103912

H. Yao, M. Yan, Z. Tong, X. Wu, Y. Yin, M.-H. Ryu, J.J. Park, T. Dai, Y. Zhao, J.H. Kim, S. Wang, Y. Zhong, M. Voskoboynik, J. Zhang, A. Kaubisch, C. Liu, Y. Chen, S.-A. Im, L. Wu, Y. Liu, E Song

引用次数: 0

查看原文本刊更多论文

P024: SHR-A1811（一种抗her2抗体药物偶联物）在her2表达或突变的重度预处理晚期实体瘤中的最新疗效和安全性：一项全球多中心i期研究

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast 医学-妇产科学

CiteScore

8.70

自引率

2.60%

发文量

165

审稿时长

59 days

期刊介绍： The Breast is an international, multidisciplinary journal for researchers and clinicians, which focuses on translational and clinical research for the advancement of breast cancer prevention, diagnosis and treatment of all stages.